47 completed, 16 recruiting, 11 unknown, 8 active not recruiting. 46 Phase 2, 25 Phase 1, 14 Not applicable, 5 Phase 3, 2 Early Phase 1.
Follow Chondrosarcoma: new trials by email Literature Review of Chondrosarcoma trials Research Report on Chondrosarcoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Clinical Applicability of Liquid Biopsy in Chondrosarcoma laboratory biomarker analysis, Molecular pathology - Chondrosarcoma of the Bone | Recruiting | Medical University of Graz | 60 | 2026-06-01 | 2026-10-07 | |
| Clear Cell Chondrosarcoma in Italy Molecular studies - Chondrosarcoma | Not applicable | Active not recruiting | Istituto Ortopedico Rizzoli | 77 | 2025-09-10 | 2026-01-22 |
| Descriptive Cohort of French Patients Treated With Carbonetherapy Since October 2010 Outside PHRC-ETOILE Questionnaire - Cancer, Cystic Carcinomas, Adenoid | Completed | Hospices Civils de Lyon | 62 | 2025-05-23 | 2025-08-06 | |
| Diagnostic and Therapeutic Targets in Cartilaginous Tumours Tumour tissue analysis, Molecular validation, Liquid biopsy analysis - Chondrosarcomas, Cartilage Tumours | Recruiting | St. Anne's University Hospital Brno, Czech Republic | 300 | 2025-05-01 | 2026-01-05 | |
| Uncovering Genes Behind Cartilage Tumors and Vascular Anomalies Using Genomic Sequencing Enchondromatosis | Recruiting | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | 100 | 2025-01-27 | 2026-10-01 | |
| PET-imaging of Two Vartumabs in Patients With Solid Tumors 89Zr-DFO-N-Suc-F8scFv, 89Zr-DFO-N-Suc-C9scFv, PET/CT scan - Solid Tumor, Colon Carcinoma | Early Phase 1 | Recruiting | Var2 Pharmaceuticals | 32 | 2024-12-10 | 2025-12-29 |
| Understanding Engagement Trends in Chondrosarcoma Clinical Trials Chondrosarcoma | Not yet recruiting | Power Life Sciences Inc. | 500 | 2024-10-01 | 2023-09-08 | |
| Enasidenib in IDH2-Mutated Malignant Sinonasal and Skull Base Tumors Enasidenib - Metastatic Chondrosarcoma, Locally Advanced Chondrosarcoma | Phase 2 | Recruiting | National Cancer Institute (NCI) | 40 | 2024-03-04 | 2026-10-16 |
| A Study to Evaluate the Utilization of 3D Printed Models in Pre-Operative Planning 3D Printed Anatomic Model, CT/MRI - Sarcoma, Ewing, Chondrosarcoma | Not applicable | Recruiting | Ricoh USA, Inc. | 150 | 2024-03-01 | 2026-02-06 |
| Grade 2 Chondrosarcoma Treated by Intralesional Curettage: Follow-up vs Resection Chondrosarcoma, Grade 2 | Completed | IRCCS Azienda Ospedaliero-Universitaria di Bologna | 62 | 2024-01-20 | 2024-12-04 | |
| Analysis of the Toxicity and Efficacy of Daily 1 vs 2 Beam Proton Therapy Proteus ONE one daily beam, Proteus ONE two daily beam - Chordoma, Chondrosarcoma | Not applicable | Recruiting | Centre Antoine Lacassagne | 106 | 2023-09-13 | 2024-09-25 |
| Hypofractionated Protontherapy in Chordomas and Chondrosarcomas of the Skull Base 5-fraction hipofractionated protontheray, 25-fraction hypofractionated proton therapy - Chordoma, Chondrosarcoma | Not applicable | Recruiting | Quironsalud | 20 | 2023-05-24 | 2026-01-23 |
| A Study of Anlotinib Combined With or Without PD-1 Antibody on Unresectable High-grade Chondrosarcoma Anlotinib hydrochloride, PD-1 inhibitor - Chondrosarcoma | Phase 2 | Unknown | Second Affiliated Hospital, Zhejiang University, School of Medicine | 70 | 2023-02-06 | 2023-02-16 |
| Adherence to a Personalized Home Exercise Program in Patients With Bone Tumor Undergoing Lower Extremity Salvage Surgery Osteosarcoma, Ewing Sarcoma | Recruiting | Istituto Ortopedico Rizzoli | 50 | 2023-01-01 | 2026-02-03 | |
| YH001 Plus Envafolimab With or Without Doxorubicin in Patients With Advanced or Metastatic Sarcoma YH001, Envafolimab, Doxorubicin - Advanced Sarcoma, Metastatic Sarcoma | Phase 1 / Phase 2 | Unknown | Tracon Pharmaceuticals Inc. | 15 | 2022-11-14 | 2023-09-21 |
| Comparing Carbon Ion Therapy, Surgery, and Proton Therapy for Management of Pelvic Sarcomas Involving the Bone Electronic Health Record Review, Quality-of-Life Assessment - Bone Sarcoma, Chondrosarcoma | Recruiting | Mayo Clinic | 72 | 2022-01-20 | 2026-03-13 | |
| IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors Bevacizumab, Glutaminase-1 Inhibitor IACS-6274, Paclitaxel - Advanced Endometrial Carcinoma, Advanced Head and Neck Squamous Cell Carcinoma | Phase 1 | Recruiting | M.D. Anderson Cancer Center | 54 | 2021-09-30 | 2026-10-06 |
| Study on Trabectedin in Advanced Rearranged Mesenchymal Chondrosarcoma Trabectedin - Mesenchymal Chondrosarcoma | Phase 2 | Recruiting | Italian Sarcoma Group | 16 | 2021-09-14 | 2026-03-27 |
| Multicohort Trial of Trabectedin and Low-dose Radiation Therapy in Advanced/Metastatic Sarcomas Trabectedin - Soft Tissue Sarcoma, Bone Tumors | Phase 2 | Unknown | Grupo Espanol de Investigacion en Sarcomas | 85 | 2021-05-28 | 2023-03-27 |
| The Registry of Oncology Outcomes Associated With Testing and Treatment Biomarker Testing (L), Systemic Treatment (T), Patient Reported Outcomes (P) - Adenocarcinoma, Adenocystic Carcinoma | Completed | Taproot Health | 167 | 2021-05-05 | 2024-12-18 |
Showing 20 of 97. Sign in to see all of them.
Sarcoma (49) · Osteosarcoma (44) · Neuroectodermal Tumors, Primitive, Peripheral (18) · Liposarcoma (16) · Melanoma (15) · Ovarian Neoplasms (15) · Fibrosarcoma (14) · Leiomyosarcoma (14) · Sarcoma, Ewing (14) · Bone Neoplasms (13) · Breast Neoplasms (13) · Chordoma (13) · Hemangiosarcoma (13) · Neoplasms (12)
Neoplasms by Histologic Type (97) · Neoplasms, Connective Tissue (97) · Neoplasms, Connective and Soft Tissue (96) · Neoplasms (85) · Sarcoma (48) · Neoplasms, Bone Tissue (45) · Neoplasms by Site (44) · Neoplasms, Germ Cell and Embryonal (43) · Neoplasms, Nerve Tissue (40) · Neoplasms, Glandular and Epithelial (38) · Neuroectodermal Tumors (33) · Endocrine System Diseases (26) · Urogenital Diseases (26) · Urogenital Neoplasms (26) · Endocrine Gland Neoplasms (25)
Doxorubicin (6) · Ifosfamide (6) · Filgrastim (5) · Docetaxel (4) · Gemcitabine (4) · Radiotherapy (4) · Carboplatin (3) · Cyclophosphamide (3) · Proton Therapy (3) · regorafenib (3) · Bevacizumab (2) · Celecoxib (2) · Chemotherapy, Adjuvant (2) · Cisplatin (2) · Epirubicin (2)
Memorial Sloan Kettering Cancer Center (6) · National Cancer Institute (NCI) (6) · Istituto Ortopedico Rizzoli (3) · M.D. Anderson Cancer Center (3) · Peking University People's Hospital (3) · SWOG Cancer Research Network (3) · Sarcoma Alliance for Research through Collaboration (3) · Centre Leon Berard (2) · Eastern Cooperative Oncology Group (2) · Grupo Espanol de Investigacion en Sarcomas (2) · Leiden University Medical Center (2) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (2) · Valerio Therapeutics (2) · AEterna Zentaris (1) · Abramson Cancer Center at Penn Medicine (1)
United States (57) · France (13) · Spain (8) · United Kingdom (6) · Australia (5) · Italy (5) · China (4) · Netherlands (4) · Ireland (3) · Puerto Rico (3) · Austria (2) · Denmark (2) · Peru (2) · South Korea (2) · Belgium (1)
Antonio Casado (2) · Claudia Valverde (2) · Josefina Cruz (2) · Robert Maki, MD, PhD (2) · Aaron H. Wolfson, MD (1) · Aaron R Weiss (1) · Alba Rubio (1) · Andrea Ferrari, MD (1) · Andrea Sambri, MD (1) · Annabel B.M. Foot (1) · Antoine Italiano (1)
PMID 31401903, PMID 16314647, PMID 18470481, PMID 19451429, PMID 19451433, PMID 20338746, PMID 20407240, PMID 21050498, PMID 22363068, PMID 22480131, PMID 23382028, PMID 24170610, PMID 24739759, PMID 24952730, PMID 27020837, PMID 28601826, PMID 29149611, PMID 30410720, PMID 30477937, PMID 31013172, PMID 31028664, PMID 31300360, PMID 32208957, PMID 32530764, PMID 32547189, PMID 32701199, PMID 32702309, PMID 32827353, PMID 33203665, PMID 33709779, PMID 33895682, PMID 34515544, PMID 34751786, PMID 35950603, PMID 37523624, PMID 38446419, PMID 39356980, PMID 39461878, PMID 39816916, PMID 40882625, PMID 41414803, PMID 41836677
U10CA032102 (3), P30CA008748 (2), 2014 (1), N01CM62206 (1), P30CA006516 (1), P30CA006973 (1), P30CA016672 (1), P30CA023108 (1), P30CA043703 (1), P30CA072720 (1), U01CA069856 (1), U01CA099168 (1), U10CA081920 (1), U10CA098543 (1), U10CA180830 (1)